![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
A Cowan, XZ Zhu, HI Mosberg, JR Omnaas and F Porreca
Department of Pharmacology, Temple University School of Medicine, Philadelphia, Pennsylvania.
The objective of this study was to describe, quantitate and compare naloxone-induced abstinence syndromes in rats infused centrally (Sylvian aqueduct) with agonists that are currently the most selective for mu [( D-Ala2, MePhe4, Gly-ol5]enkephalin), delta [( D-Pen2, D- Pen5]enkephalin) and kappa (3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl) cyclohexyl]benzeneacetamide) (U-50,488H) opioid receptors, respectively. Morphine, ethylketazocine and dynorphin A served as reference compounds. After 70 hr of infusion from s.c. implanted osmotic minipumps, three levels of abstinence were associated with the injection of naloxone (3 mg/kg s.c.): 1) negligible syndromes (scores of less than 21) were obtained in rats on water or the kappa-directed ligands, U-50,488H and dynorphin A; 2) a low-to-moderate abstinence score (37-38) was recorded with rats receiving [D-Pen2, D- Pen5]enkephalin and ethylketazocine; and 3) a high abstinence score (64- 73) was obtained with rats on morphine and DAGO. These results reinforce the concept of developing selective, nonbenzomorphan kappa agonists as clinically useful analgesics and emphasize that, when evaluating new analgesics, high selectivity for delta receptors does not, in itself, guarantee freedom from physical dependence.
This article has been cited by other articles:
|
|
 |
|
  S. P. Hack, E. E. Bagley, B. C. H. Chieng, and M. J. Christie Induction of {delta}-Opioid Receptor Function in the Midbrain after Chronic Morphine Treatment J. Neurosci., March 23, 2005; 25(12): 3192 - 3198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Fadhil, R. Schmidt, C. Walpole, and K. A. Carpenter Exploring Deltorphin II Binding to the Third Extracellular Loop of the {delta}-Opioid Receptor J. Biol. Chem., May 14, 2004; 279(20): 21069 - 21077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-G. Liu and P. L. Prather Chronic Agonist Treatment Converts Antagonists into Inverse Agonists at delta -Opioid Receptors J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1070 - 1079. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Brandt, M. S. Furness, K. C. Rice, B. D. Fischer, and S. S. Negus Studies of Tolerance and Dependence with the delta -Opioid Agonist SNC80 in Rhesus Monkeys Responding under a Schedule of Food Presentation J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 629 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Quock, T. H. Burkey, E. Varga, Y. Hosohata, K. Hosohata, S. M. Cowell, C. A. Slate, F. J. Ehlert, W. R. Roeske, and H. I. Yamamura The delta -Opioid Receptor: Molecular Pharmacology, Signal Transduction, and the Determination of Drug Efficacy Pharmacol. Rev., September 1, 1999; 51(3): 503 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. W. D. Matthes, C. Smadja, O. Valverde, J.-L. Vonesch, A. S. Foutz, E. Boudinot, M. Denavit-Saubie, C. Severini, L. Negri, B. P. Roques, et al. Activity of the delta -Opioid Receptor Is Partially Reduced, Whereas Activity of the kappa -Receptor Is Maintained in Mice Lacking the µ-Receptor J. Neurosci., September 15, 1998; 18(18): 7285 - 7295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Bot, A. D. Blake, S. Li, and T. Reisine Opioid Regulation of the Mouse delta -Opioid Receptor Expressed in Human Embryonic Kidney 293 Cells Mol. Pharmacol., August 1, 1997; 52(2): 272 - 281. [Abstract] [Full Text]
|
|
|
|
|
|
M. Valiquette, H. K. Vu, S. Y. Yue, C. Wahlestedt, and P. Walker Involvement of Trp-284, Val-296, and Val-297 of the Human delta -Opioid Receptor in Binding of delta -Selective Ligands J. Biol. Chem., August 2, 1996; 271(31): 18789 - 18796. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
